Swiss Type Amyloid Polyneuropathy

Authored by

mohammad looti

October 9, 2025

Swiss Type Amyloid Polyneuropathy

Primary Disciplinary Field(s): Neurology, Genetics, Nephrology, Internal Medicine

1. Core Definition

Swiss Type Amyloid Polyneuropathy (STAP), often classified clinically as a form of non-transthyretin related familial amyloid polyneuropathy (FAP) or systemic Apolipoprotein A-I (ApoA-I) amyloidosis, is an exceptionally rare, inherited disorder characterized by the extracellular deposition of abnormal, misfolded protein fibrils. These amyloid deposits, primarily derived from fragments of the ApoA-I protein, accumulate in various tissues throughout the body, leading to progressive organ dysfunction. Unlike the more prevalent forms of hereditary amyloidosis, such as TTR-related FAP, the Swiss Type is primarily defined by a clinical triad involving significant peripheral neuropathy, pronounced autonomic dysfunction, and frequently, severe renal compromise, particularly nephrotic syndrome. The condition follows an autosomal dominant inheritance pattern, meaning a mutation in just one copy of the associated gene is sufficient to cause the disease, leading to substantial phenotypic variability even within the same pedigree.

The nomenclature "Swiss Type" historically reflects the geographical or institutional location associated with its initial detailed clinical description or the identification of a significant cluster of affected families. This designation helps distinguish it pathologically and genetically from other FAP subtypes. STAP is classified biochemically as ALys/AApoA-I amyloidosis, emphasizing that the fibril precursor is the Apolipoprotein A-I protein. The systemic nature of STAP necessitates a multi-disciplinary approach to diagnosis and management, as the pathology affects numerous systems simultaneously, including the peripheral and autonomic nervous systems, the kidneys, and often the cardiovascular system, requiring coordination among specialists ranging from neurologists and geneticists to nephrologists and cardiologists.

The defining feature of amyloidosis is the transformation of soluble proteins into insoluble, structurally rigid fibrils that exhibit a characteristic beta-sheet conformation when stained with Congo Red and viewed under polarized light. In STAP, the precursor protein is ApoA-I, a major component of high-density lipoprotein (HDL). The mutations in the gene encoding ApoA-I disrupt the protein's native structure, making it prone to misfolding and aggregation. These aggregates subsequently deposit in the interstitium and basement membranes of vital organs, leading to pressure, inflammation, and eventual organ failure. The resulting damage to the peripheral nerves--the polyneuropathy--is typically progressive, debilitating, and often symmetric, starting distally and moving proximally, significantly impacting quality of life and lifespan if left untreated.

2. Genetic Basis and Pathology

The underlying genetic defect responsible for Swiss Type Amyloid Polyneuropathy resides within

the *APOA1* gene, located on chromosome 11 (11q23-q24). This gene provides instructions for making apolipoprotein A-I, which is synthesized predominantly in the liver and intestine. Mutations in *APOA1* are inherited in an **autosomal dominant** manner. Numerous mutations have been identified, including point mutations such as Arg173Pro, Leu60Arg, and Gly26Arg, among others. These specific mutations often dictate the clinical phenotype and the predominant organs affected, although all result in the production of structurally unstable ApoA-I variants that readily misfold and aggregate. The ApoA-I protein is normally crucial for cholesterol efflux and reverse cholesterol transport; however, its mutation transforms it into a pathogenic agent.

The pathology of STAP involves the systematic breakdown of the mutant ApoA-I protein into smaller, amyloidogenic fragments. It is these N-terminal fragments, rather than the full-length protein, that form the toxic amyloid fibrils. These fragments are highly resistant to degradation by cellular proteasomes, allowing them to accumulate exponentially over time. Unlike Transthyretin (TTR) amyloidosis, where the TTR protein is predominantly produced by the liver, ApoA-I amyloidosis involves a protein produced in multiple sites, though the liver is the primary source of the circulating mutant protein that seed the deposits. This systemic production contributes to the widespread deposition seen in STAP, although certain organs exhibit a pronounced susceptibility.

Histopathologically, the defining feature is the presence of amyloid deposits confirmed by Congo Red staining. In STAP patients, deposits are frequently massive in the kidneys, especially within the glomeruli and tubulointerstitium, leading rapidly to nephrotic syndrome and progressive renal insufficiency. Neuropathic involvement stems from the deposition of fibrils in the endoneurium and surrounding the blood vessels (vasa nervorum) of the peripheral nerves, resulting in ischemia, demyelination, and axonal loss. While cardiac involvement is less universally dominant than in TTR amyloidosis, it can occur, affecting the myocardium or the conduction system, contributing to morbidity and mortality. The degree of tissue infiltration is directly correlated with the severity and progression rate of organ dysfunction, underscoring the critical role of the ApoA-I mutation in driving tissue damage.

3. Clinical Presentation and Phenomenology

The clinical presentation of Swiss Type Amyloid Polyneuropathy is classically distinguished by a significant overlap of neurological and systemic manifestations, often starting in the third or fourth decade of life, though onset can be highly variable depending on the specific mutation. The polyneuropathy typically begins insidiously, presenting as distal, symmetric sensory loss, often preceded by paresthesias and dysesthesias in the lower extremities. As the disease progresses, patients develop severe motor deficits, leading to muscle weakness, atrophy, and difficulty with ambulation. Crucially, pain, which is often a dominating symptom in other peripheral neuropathies, might be reduced or absent late in the disease due to severe loss of small fiber function.

A hallmark feature separating STAP from many other types of FAP is the prominence and early onset of **renal involvement**. Patients frequently develop heavy proteinuria, often reaching levels indicative of nephrotic syndrome. This kidney pathology is often the most life-threatening component of the disease, resulting in hypoalbuminemia, severe edema, and ultimately, end-stage renal disease (ESRD), necessitating dialysis or transplantation. Autonomic neuropathy is also a nearly universal and often devastating component, manifesting as severe orthostatic hypotension (a drop in blood pressure upon standing), refractory diarrhea alternating with constipation, sexual dysfunction, and abnormalities in sweating. The severity of autonomic dysfunction frequently contributes significantly to the patient's disability and risk of sudden cardiac events.

Beyond the neurological and renal systems, STAP can involve the gastrointestinal tract (leading to motility disorders and malabsorption), the eyes (vitreous opacities are less common than in TTR amyloidosis but can occur), and the cardiovascular system. Cardiac involvement, though secondary to the primary neurological and renal picture, includes restrictive cardiomyopathy, arrhythmias, and conduction blocks, significantly increasing the risk of mortality. The constellation of progressive peripheral neuropathy, profound autonomic dysfunction, and rapidly advancing renal failure necessitates early recognition and aggressive management to mitigate the widespread, cumulative organ damage caused by ApoA-I amyloid deposition.

4. Diagnosis and Differential Considerations

The diagnosis of Swiss Type Amyloid Polyneuropathy requires a high index of suspicion, given its rarity, and involves a multi-step process integrating clinical presentation, tissue biopsy confirmation, and genetic testing. Clinically, suspicion is raised when a patient presents with a progressive, axonal polyneuropathy combined with unexplained nephrotic syndrome or severe autonomic dysfunction, especially if there is a positive family history consistent with autosomal dominant inheritance. Electromyography (EMG) and nerve conduction studies confirm the presence of an axonal, usually length-dependent, sensorimotor polyneuropathy, often with evidence of severe small fiber dysfunction revealed through quantitative sudomotor axon reflex testing (QSART).

The definitive diagnosis relies on histological confirmation of amyloid deposits in affected tissues, typically obtained via a biopsy of the abdominal fat pad, rectum, or affected organ (e.g., kidney or nerve). Once amyloid is confirmed via Congo Red staining, the specific type of amyloid protein must be identified. This is critically achieved through immunohistochemistry, mass spectrometry-based proteomic analysis, or specialized immune-electron microscopy. Identifying the fibrils as being derived from **Apolipoprotein A-I** is essential to confirming the diagnosis of STAP and ruling out other forms of systemic amyloidosis, such as AL amyloidosis (light chain) or hereditary TTR amyloidosis.

Differential diagnosis is crucial and complex. STAP must be differentiated primarily from other hereditary amyloid polyneuropathies, particularly TTR amyloidosis, which typically presents with prominent cardiac and vitreous involvement but less severe, or later-onset, nephropathy. It must also be distinguished from acquired AL amyloidosis, which typically occurs later in life, is associated with a plasma cell dyscrasia, and usually presents with more severe cardiac involvement. Non-amyloid polyneuropathies, such as chronic inflammatory demyelinating polyneuropathy (CIDP) or diabetic neuropathy, must also be excluded. Finally, genetic testing for mutations in the *APOA1* gene is mandatory to confirm the hereditary nature of STAP and to allow for genetic counseling and predictive testing of at-risk family members.

5. Historical Context and Nomenclature

The identification and description of hereditary systemic amyloidosis progressed significantly throughout the mid-to-late 20th century, culminating in the molecular understanding of various precursor proteins. While the most recognized hereditary form is associated with transthyretin (TTR) and often bears the names of the regions where it was first described (e.g., Portuguese or Japanese types), the Swiss Type designation emerged from the recognition of specific ApoA-I related amyloidosis in families initially studied by researchers in Switzerland, or having ancestral ties to the region. This nomenclature helped catalog a distinct clinical entity whose pathogenesis was clearly separate from the dominant TTR mutations.

Early classifications of familial amyloid polyneuropathy were based largely on clinical phenotype and geographic prevalence. As biochemical techniques improved, allowing for the precise sequencing and identification of the misfolded precursor protein, the classification shifted towards a molecular basis. The realization that ApoA-I mutations could lead to systemic amyloidosis established a new category of hereditary disease. The identification of the specific *APOA1* mutations confirmed that this type was a unique entity, characterized by its propensity for renal involvement, which was clinically distinct from the TTR variants. This molecular identification solidified its recognition as a separate disease entity within the larger spectrum of systemic amyloidosis.

The transition from purely clinical descriptors like "Swiss Type" to the molecular designation of ApoA-I amyloidosis reflects the advancement in understanding the disease mechanisms. However, the historical terms often persist in clinical practice. Today, STAP serves as a key example of how a single protein, ApoA-I, essential for lipid metabolism, can become profoundly pathogenic when structurally compromised by genetic mutation. Recognition of the ApoA-I variant as the specific cause was instrumental in focusing therapeutic research away from TTR targets and towards strategies aimed at inhibiting or stabilizing the ApoA-I protein, marking a significant milestone in the history of inherited amyloid disorders.

6. Treatment Modalities and Management

Management of Swiss Type Amyloid Polyneuropathy remains challenging and focuses heavily on supportive care, symptom management, and, increasingly, on targeted interventions aimed at reducing the production or enhancing the clearance of the mutant ApoA-I protein. Because the liver is the primary source of circulating ApoA-I, **liver transplantation** has historically been considered a curative option for STAP, similar to its role in TTR amyloidosis. By replacing the patient's liver with a healthy donor organ, the source of the mutant protein is removed, thereby halting the production of new amyloidogenic ApoA-I fragments.

While liver transplantation can stabilize or improve the progression of neuropathy and other systemic symptoms, its efficacy in reversing advanced organ damage, particularly severe renal or cardiac involvement, is limited. Furthermore, the decision for transplantation must weigh the risks of major surgery against the aggressive nature of the disease. If severe renal failure has already occurred, a combined liver and kidney transplantation may be necessary. Supportive care is paramount, involving aggressive management of renal complications (e.g., dialysis, fluid management, proteinuria reduction), treatment of autonomic symptoms (e.g., pharmacological support for orthostatic hypotension), and physical therapy to maintain mobility despite progressive neuropathy.

Recent therapeutic advancements in amyloidosis, particularly RNA interference (RNAi) therapies and antisense oligonucleotides (ASOs), which target the mRNA of the precursor protein to inhibit its synthesis, hold theoretical promise for STAP. However, the development pipeline for ApoA-I specific stabilizers or reducers is less mature than for TTR. Nevertheless, future treatment strategies are centered on genetic silencing techniques to reduce the pathological ApoA-I load, potentially offering a non-surgical alternative to liver transplantation and fundamentally altering the disease course by eliminating the source of amyloid formation. Research into developing drugs that enhance the dissolution of existing ApoA-I amyloid fibrils is also a major area of investigation.

7. Prognosis and Disease Progression

The prognosis for individuals diagnosed with Swiss Type Amyloid Polyneuropathy is generally guarded, reflecting the aggressive and systemic nature of the amyloid deposition, particularly the often rapid progression toward end-stage renal disease (ESRD). Without specific therapeutic intervention, the disease leads to profound disability due to severe sensorimotor and autonomic neuropathy, often resulting in dependency on mobility assistance. The most common causes of morbidity and mortality are related to progressive renal failure, necessitating renal replacement therapy, and complications arising from autonomic dysfunction, including malnutrition, severe orthostatic hypotension, and sudden cardiac events.

The rate of progression is highly dependent on the specific *APOA1* mutation present, the patient's

age of onset, and the promptness of diagnosis and intervention. Earlier onset is often correlated with a more aggressive disease course. For patients receiving liver transplantation, the long-term prognosis improves significantly as the primary source of the pathogenic protein is eliminated. However, amyloid deposits that formed prior to transplantation are often slow to resolve, and progression of pre-existing amyloid-related damage, particularly within the nervous system and kidneys, may continue for some time post-transplant. Therefore, the long-term success of treatment is directly tied to intervening before irreversible organ damage has occurred.

Given the rarity of STAP, comprehensive data on long-term survival rates post-diagnosis are limited compared to more common amyloidosis types. However, ongoing research efforts focusing on gene-silencing therapies aim to shift the natural history of the disease. Effective management today requires vigilant monitoring of renal function, meticulous control of autonomic symptoms, and timely consideration of liver transplantation. Improved genetic screening and diagnostic techniques are crucial for identifying affected individuals earlier, offering a wider window for effective intervention and thereby improving the overall quality of life and potentially extending lifespan for those afflicted by this devastating disorder.

Further Reading

Apolipoprotein A1 (ApoA-I) Amyloidosis
APOA1 Amyloidosis - GeneReviews
Amyloidosis Foundation on ApoA-I